Exogenous MG53 Protein for Tissue Performance Enhancement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods fail to effectively improve the performance of otherwise healthy, non-diseased, and non-acutely injured muscle and organ tissues, as the endogenous MG53 levels are insufficient to overcome reduced tissue performance, and exogenous administration of MG53 has been therapeutically ineffective for conditions like multiple sclerosis, viral infections, and obesity.
Innovation Solution
Administration of exogenous MG53, potentially combined with antioxidants and zinc salts, to improve tissue performance by enhancing muscle contraction, Ca2+ signaling, muscle satellite cell proliferation, and overall tissue function in healthy tissues, including skeletal, cardiac, and neuronal tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exogenous MG53 is administered to improve tissue performance, then tissue function improves, but the treatment is ineffective for certain conditions like multiple sclerosis, viral infections, and obesity
Solution Approach 1:
The patent applies local quality by targeting specific tissue types (skeletal muscle, cardiac muscle, kidney, neuronal tissue) with MG53 administration rather than attempting a universal treatment approach. The invention recognizes that MG53 has particular efficacy in muscle and organ tissues where it can directly enhance cellular function, while acknowledging its limitations in other condition types.
2Reliability
If endogenous MG53 levels are increased to improve tissue performance, then tissue function improves, but the natural levels are insufficient to overcome reduced performance
Solution Approach 1:
The patent applies preliminary action by administering exogenous MG53 before tissue performance deteriorates further or in conjunction with lifestyle interventions. The composition is designed to proactively enhance tissue function by supplementing MG53 levels before endogenous production can adequately respond to performance demands.
Solution Approach 2:
The patent uses an intermediary approach by employing a composition that delivers MG53 in a bioavailable form, potentially combined with antioxidants and zinc salts that facilitate MG53 stability and uptake. This intermediary composition bridges the gap between insufficient endogenous MG53 and the higher levels needed for improved tissue performance.
3Reliability
If MG53 is used to treat acutely injured or chronically injured tissue, then repair is achieved, but it does not improve performance of healthy tissue with reduced function
Solution Approach 1:
The patent applies inversion by reversing the traditional therapeutic approach: instead of using MG53 only when tissue is already injured or diseased, the invention administers MG53 to healthy tissue to prevent performance reduction and maintain optimal function. This proactive application expands the therapeutic window beyond repair scenarios.
Data Source
AI summary
Compositions for and methods of improving tissue function are provided. Said compositions comprise MG53 or express MG53. Said compositions can be used for improving the function of non-diseased and uninjured tissue in subjects.